Chimeric Animal Immune Response Innovation

The original patent disclosed methods for obtaining adult individuals from xenogeneic or allogeneic chimeric animal fetuses, but it did not address the specific challenges of immune response and inflammation in unique operational environments. The present invention fills this gap by providing specialized solutions for high-security research, disaster relief, and extreme weather conditions.

The new claims provide a novel and non-obvious solution by adapting the original patent's methods and compositions for specialized applications in high-security facilities, disaster relief scenarios, and extreme weather conditions. The inventive step lies in the recognition of the need for tailored solutions for these unique environments and the development of specific formulations, systems, and methods to address them.

Alternative embodiments of the invention could include the use of different types of chimeric animals, such as those with genetic modifications or induced pluripotent stem cells. Variations of the composition and system could include different formulations of the anti-inflammatory agent or immunosuppressive agent, or the use of additional components to enhance their efficacy. Other operational environments, such as space exploration or high-altitude research, could also be targeted by adapting the invention's components and methods.

The invention has significant commercial potential in the fields of biotechnology, pharmaceuticals, and life sciences. The high-security research market, disaster relief industry, and extreme weather condition applications could benefit from the invention's specialized solutions. Additionally, the invention could have implications for human health and disease research, as well as veterinary medicine.